Predicting Clinical Remission of Chronic Urticaria Using Random Survival Forests: Machine Learning Applied to Real-World Data.
Chronic urticaria
Electronic health records
Machine learning
Predictors
Random survival forest
Remission
Time to clinical remission
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
22
06
2022
accepted:
28
09
2022
pubmed:
28
10
2022
medline:
28
10
2022
entrez:
27
10
2022
Statut:
ppublish
Résumé
The time required to reach clinical remission varies in patients with chronic urticaria (CU). The objective of this study is to develop a predictive model using a machine learning methodology to predict time to clinical remission for patients with CU. Adults with ≥ 2 ICD-9/10 relevant CU diagnosis codes/CU-related treatment > 6 weeks apart were identified in the Optum deidentified electronic health record dataset (January 2007 to June 2019). Clinical remission was defined as ≥ 12 months without CU diagnosis/CU-related treatment. A random survival forest was used to predict time from diagnosis to clinical remission for each patient based on clinical and demographic features available at diagnosis. Model performance was assessed using concordance, which indicates the degree of agreement between observed and predicted time to remission. To characterize clinically relevant groups, features were summarized among cohorts that were defined based on quartiles of predicted time to remission. Among 112,443 patients, 73.5% reached clinical remission, with a median of 336 days from diagnosis. From 1876 initial features, 176 were retained in the final model, which predicted a median of 318 days to remission. The model showed good performance with a concordance of 0.62. Patients with predicted longer time to remission tended to be older with delayed CU diagnosis, and have more comorbidities, more laboratory tests, higher body mass index, and polypharmacy during the 12-month period before the first CU diagnosis. Applying machine learning to real-world data enabled accurate prediction of time to clinical remission and identified multiple relevant demographic and clinical variables with predictive value. Ongoing work aims to further validate and integrate these findings into clinical applications for CU management.
Identifiants
pubmed: 36301485
doi: 10.1007/s13555-022-00827-6
pii: 10.1007/s13555-022-00827-6
pmc: PMC9674814
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2747-2763Informations de copyright
© 2022. The Author(s).
Références
Transplantation. 2020 May;104(5):1095-1107
pubmed: 31403555
Sci Rep. 2020 Nov 10;10(1):19480
pubmed: 33173057
JAMA. 1982 May 14;247(18):2543-6
pubmed: 7069920
Int Arch Allergy Immunol. 2016;169(4):263-6
pubmed: 27240837
Allergol Int. 2019 Jan;68(1):52-58
pubmed: 29945815
Allergy Asthma Immunol Res. 2021 May;13(3):390-403
pubmed: 33733635
Allergy. 2018 Jul;73(7):1393-1414
pubmed: 29336054
AMIA Jt Summits Transl Sci Proc. 2020 May 30;2020:191-200
pubmed: 32477638
Dermatol Ther (Heidelb). 2022 Jan;12(1):15-27
pubmed: 34807372
F1000Res. 2017 Jul 11;6:1095
pubmed: 28751972
Ann Allergy Asthma Immunol. 2009 Nov;103(5):407-10
pubmed: 19927539
J Dent Res. 2012 Feb;91(2):142-9
pubmed: 21876032
Allergy. 2004 Aug;59(8):869-73
pubmed: 15230821
J Allergy Clin Immunol. 2018 May;141(5):1726-1734
pubmed: 29438771
Allergy. 2011 Mar;66(3):317-30
pubmed: 21083565
Curr Opin Allergy Clin Immunol. 2011 Oct;11(5):457-63
pubmed: 21822129
Allergy. 2020 Feb;75(2):423-432
pubmed: 31494963
JAMA. 2018 Apr 3;319(13):1317-1318
pubmed: 29532063
BMJ. 1995 Jan 21;310(6973):170
pubmed: 7833759
J Dermatol. 2007 May;34(5):294-301
pubmed: 17408437
Value Health. 2022 Jul;25(7):1063-1080
pubmed: 35779937
Allergy Asthma Proc. 2019 Jul 1;40(4):273-278
pubmed: 31262381
Asian Pac J Cancer Prev. ;18(1):129-134
pubmed: 28240020
Allergy Asthma Clin Immunol. 2020 Jul 15;16:63
pubmed: 32834828
PLoS One. 2018 Aug 31;13(8):e0202344
pubmed: 30169498
J Eur Acad Dermatol Venereol. 2018 Feb;32(2):276-281
pubmed: 28846167
J Allergy Clin Immunol. 2014 May;133(5):1270-7
pubmed: 24766875
Ther Adv Chronic Dis. 2015 Nov;6(6):304-13
pubmed: 26568807
Allergy Asthma Immunol Res. 2018 Jan;10(1):83-87
pubmed: 29178681
Scand J Caring Sci. 2013 Jun;27(2):487-92
pubmed: 22862286
Allergy Asthma Clin Immunol. 2019 Sep 11;15:56
pubmed: 31528163
Am Fam Physician. 2017 Jun 1;95(11):717-724
pubmed: 28671445
Artif Intell Med. 2001 Aug;23(1):89-109
pubmed: 11470218
Circ Cardiovasc Qual Outcomes. 2011 Jan 1;4(1):39-45
pubmed: 21098782
Allergy. 2021 Oct;76(10):2965-2981
pubmed: 33539587